Verdiva Bio

Verdiva Bio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and other cardiometabolic disorders. They are advancing a portfolio of next-generation oral and injectable treatments with first-in-class or best-in-class potential, including a once-weekly oral GLP-1 receptor agonist and an oral amylin agonist.

Buy Funded Startups lists

Funding Round: Series A

Funding Amount: $411M

Date: 09-Jan-2025

Investors: Forbion, General Atlantic, RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, LYFE Capital

Markets: Biopharmaceutical, Cardiometabolic, Obesity

HQ: London, England, United Kingdom

Founded: 2024

Website: https://www.verdivabio.com

LinkedIn: https://www.linkedin.com/company/verdivabio

Twitter:

Instagram: